A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study is a multisite, randomized, double-blind, placebo-controlled, phase 2/3 study of
MG01CI (1400 mg daily) for 6 weeks compared with placebo in a 1:1 ratio of 300 adults with
ADHD.